MedTrace Logo

FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

NCT04219969 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-05-09

No results posted yet for this study

Summary

To compare the results and understand the possible benefits from FDG-PET/MRI during different scanning time points after FDG, a type of contrast drug, is given.

Conditions

  • Spinal Cord Neoplasm

Interventions

DRUG

Fludeoxyglucose F-18

Given IV

DEVICE

Magnetic Resonance Imaging

Undergo PET-MRI

PROCEDURE

Positron Emission Tomography

Undergo PET-MRI

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Maria K Gule-Monroe · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-21
Primary Completion
2024-05-07
Completion
2024-05-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04219969 on ClinicalTrials.gov